Evidence map›Paper›PMID 36457227›Full record

ArticleExperimental dermatology2023

c-Src activation as a potential marker of chemical-induced skin irritation using tissue-engineered skin equivalents.

Amy L Harding, Helen E Colley, Inmaculada Barragan Vazquez, Simon Danby, Md Zobaer Hasan, Hirofumi Nakanishi, Tetsuo Furuno, Craig Murdoch

Open access · hybridAbstract read
In one paragraph

Article in Experimental dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Elucidating the Multi-Target Anti-Pruritic Mechanism ofCurrent issues in molecular biology · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Amy L HardingSchool of Clinical Dentistry, University of Sheffield, Sheffield, UK.
Helen E ColleySchool of Clinical Dentistry, University of Sheffield, Sheffield, UK.ORCID 0000-0003-0053-7468
Inmaculada Barragan VazquezSchool of Clinical Dentistry, University of Sheffield, Sheffield, UK.
Simon DanbySheffield Dermatology Research, Department of Infection, Immunity & Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
Md Zobaer HasanRohto Pharmaceutical Co., Ltd., Safety Design Centre, Kyoto, Japan.ORCID 0000-0001-7174-4443
Hirofumi NakanishiRohto Pharmaceutical Co., Ltd., Safety Design Centre, Kyoto, Japan.
Tetsuo FurunoRohto Pharmaceutical Co., Ltd., Safety Design Centre, Kyoto, Japan.
Craig MurdochSchool of Clinical Dentistry, University of Sheffield, Sheffield, UK.
University of Sheffield · GBRohto Pharmaceutical (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin irritancy to topically applied chemicals is a significant problem that affects millions of people worldwide. New or modified chemical entities must be tested for potential skin irritancy by industry as part of the safety and toxicity profiling process. Many of these tests have now moved to a non-animal-based format to reduce experiments on animals. However, these tests for irritancy potential often rely on monolayer cultures of keratinocytes that are not representative of the skin architecture or tissue-engineered human skin equivalents (HSE) using complex multi-gene expression panels that are often cumbersome and not amenable for high throughput. Here, we show that human skin equivalents increase abundance of several phosphorylated kinases (c-Src, c-Jun, p53, GSK3α/β) in response to irritant chemical stimulation by phosphokinase array analysis. Specific phosphorylation of c-Src

Indexed as

IrritantsSkin DiseasesAllergensAnimalsHumansKeratinocytesSkinAllergensIrritantsc-Srcirritationsignal transductionskintoxicity

Identifiers

PMID36457227
PMCPMC10946902
OpenAlexW4311114935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.